Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Bernard Guillot
Based on 29 articles published since 2010
(Why 29 articles?)
||||

Between 2010 and 2020, B. Guillot wrote the following 29 articles about Melanoma.
 
+ Citations + Abstracts
Pages: 1 · 2
1 Guideline [New guidelines for stage III melanoma (the French Cutaneous Oncology Group)]. 2019

Guillot, B / Dupuy, A / Pracht, M / Jeudy, G / Hindie, E / Desmedt, E / Jouary, T / Leccia, M-T. ·Département de dermatologie, université de Montpellier, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · Service de dermatologie, CHU de Rennes, 35033 Rennes, France. · Département d'oncologie médicale, centre Eugène-Marquis, 35000 Rennes, France. · Service de dermatologie, CHU de Dijon, Dijon, 21079 France. · Service de médecine nucléaire, CHU de Bordeaux, Bordeaux, 33076 France. · Service de dermatologie, CHU de Lille, 59037 Lille, France. · Service d'oncologie, centre hospitalier de Pau, 64000 Pau, France. · Service de dermatologie, CHU de Grenoble, 38043 Grenoble, France. ·Ann Dermatol Venereol · Pubmed #30833037.

ABSTRACT: Improved knowledge of sentinel node procedures coupled with the results of adjuvant clinical trials in stage III melanoma have prompted the French Cutaneous Oncology Group to propose new guidelines for the management of stage III melanoma. These guidelines comply with the principles of the evidence-based medicine.

2 Guideline [Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. 2018

Guillot, B / Charles, J / Jeudy, G / Cupissol, D / Dupuy, A / Dutriaux, C / Gangloff, D / Magne, N / Mirabel, X / M'Sadek, A / Pracht, M / Sichel, C / Do Outeiro, G. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · CHU de Grenoble, 38700 Grenoble, France. · CHU de Dijon, 21000 Dijon, France. · Institut du Cancer de Montpellier, 34298 Montpellier, France. · CHU de Rennes, 35000 Rennes, France. · CHU de Bordeaux, 33000 Bordeaux, France. · Institut universitaire du cancer de Toulouse, 31100 Toulouse, France. · Institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France. · Centre Oscar-Lambret, 59000 Lille, France. · Centre Eugène-Marquis, 35000 Rennes, France. · 13470 Carnoux en Provence, France. · Institut national du cancer de Boulogne-Billancourt, 92100 Boulogne-Billancourt, France. ·Ann Dermatol Venereol · Pubmed #29703640.

ABSTRACT: -- No abstract --

3 Guideline French updated recommendations in Stage I to III melanoma treatment and management. 2017

Guillot, B / Dalac, S / Denis, M G / Dupuy, A / Emile, J F / De La Fouchardiere, A / Hindie, E / Jouary, T / Lassau, N / Mirabel, X / Piperno Neumann, S / De Raucourt, S / Vanwijck, R. ·Dermatology Department, CHU Montpellier. · Dermatology Department, CHU Dijon. · Laboratory of Biochemistry, CHU Nantes. · Dermatology Department, CHU Rennes. · Laboratory of Pathology, AP-HP Ambroise Paré Hospital, Boulogne, France. · Laboratory of Pathology, Centre Léon Bérard Lyon. · Department of Nuclear medicine, CHU Bordeaux. · Dermatology Department, CH Pau. · Department of Radiology, Institut Gustave Roussy Villejuif. · Department of Radiotherapy, Centre Oscar Lambret Lille. · Institut Curie, Paris, France. · 1 Avenue du 6 Juin, 1945, 14000 Caen, France. · Louvain Catholic University, Brussels, Belgium. ·J Eur Acad Dermatol Venereol · Pubmed #28120528.

ABSTRACT: As knowledge continues to develop, regular updates are necessary concerning recommendations for practice. The recommendations for the management of melanoma stages I to III were drawn up in 2005. At the request of the Société Française de Dermatologie, they have now been updated using the methodology for recommendations proposed by the Haute Autorité de Santé in France. In practice, the principal recommendations are as follows: for staging, it is recommended that the 7th edition of AJCC be used. The maximum excision margins have been reduced to 2 cm. Regarding adjuvant therapy, the place of interferon has been reduced and no validated emerging medication has yet been identified. Radiotherapy may be considered for patients in Stage III at high risk of relapse. The sentinel lymph node technique remains an option. Initial examination includes routine ultrasound as of Stage II, with other examinations being optional in stages IIC and III. A shorter strict follow-up period (3 years) is recommended for patients, but with greater emphasis on imaging.

4 Guideline [Update to the recommendations for management of melanoma stages I to III]. 2016

Guillot, B / Dalac, S / Denis, M G / Dupuy, A / Emile, J-F / De La Fouchardière, A / Hindie, E / Jouary, T / Lassau, N / Mirabel, X / Piperno Neumann, S / De Raucourt, S / Vanwijck, R. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier cedex 5, France. Electronic address: b-guillot@chu-montpellier.fr. · Service de dermatologie, hôpital du Bocage sud, CHU de Dijon, BP 1542, 21079 Dijon cedex, France. · Laboratoire de biochimie, institut de biologie, 9, quai Moncousu, 44093 Nantes cedex, France. · Service de dermatologie, CHU de Rennes, Rennes, France. · Service d'anatomie pathologique, CHU Ambroise-Paré-Boulogne, 92104 Boulogne cedex, France. · Centre anticancéreux Léon-Bérard, 28, rue Laennec, 69008 Lyon, France. · Service de médecine nucléire Sud et Pellegrin, CHU de Bordeaux, Bordeaux, France. · Service de médecine, centre hospitalier de Pau, 64000 Pau, France. · Service d'imagerie médicale, institut Gustave-Roussy, 94800 Villejuif, France. · Centre Oscar-Lambret, 3, rue Fréderic-Combemale, 59000 Lille, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · 1, avenue du 6-Juin, 14000 Caen, France. · Université catholique de Louvain, 10, avenue Hippocrate, 1200 Bruxelles, Belgique. ·Ann Dermatol Venereol · Pubmed #27527567.

ABSTRACT: As knowledge continues to develop, regular updates are necessary concerning recommendations for practice. The recommendations for the management of melanoma stages I to III were drawn up in 2005. At the request of the Société Française de Dermatologie, they have now been updated using the methodology for recommendations proposed by the Haute Autorité de Santé. In practice, the principal recommendations are as follows: for staging, it is recommended that the 7th edition of AJCC be used. The maximum excision margins have been reduced to 2cm. Regarding adjuvant therapy, the place of interferon has been reduced and no validated emerging medication has yet been identified. Radiotherapy may be considered for patients in stage III at high risk of relapse. The sentinel lymph node technique remains an option. Initial examination includes routine ultrasound as of stage II, with other examinations being optional in stages IIC and III. A shorter strict follow-up period (3years) is recommended for patients, but with greater emphasis on imaging.

5 Guideline [Guidelines for stage I to III melanoma]. 2016

Guillot, Bernard / Dalac, Sophie / Denis, Marc / Dupuy, Alain / Emile, Jean François / De La Fouchardiere, Arnaud / Hindie, Elif / Jouary, Thomas / Lassau, Nathalie / Mirabel, Xavier / Piperno Neumann, Sophie / De Raucourt, Sixtine / Vanwijck, Romain. ·Département de dermatologie, hôpital Saint-Eloi, CHU de Montpellier, 34295 Montpellier cedex 5, France. Electronic address: b-guillot@chu-montpellier.fr. · Service de dermatologie, hôpital du Bocage sud, CHU de Dijon, BP 1542, 21079 Dijon cedex, France. · Laboratoire de biochimie, institut de biologie, 9, quai Moncousu, 44093 Nantes cedex, France. · Service de dermatologie, CHU de Rennes, Rennes, France. · Service d'anatomie pathologique, CHU Ambroise-Paré Boulogne, 92104 Boulogne cedex, France. · Centre anticancéreux Léon-Bérard, 28, rue Laennec, 69008 Lyon, France. · Service de médecine nucléire sud et pellegrin, CHU de Bordeaux, Bordeaux, France. · Service de médecine, CH de Pau, 64000 Pau, France. · Service d'imagerie médicale, institut Gustave-Roussy, 94800 Villejuif, France. · Centre Oscar-Lambret, 3, rue Fréderic-Combemale, 59000 Lille, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Sixtine, 1, avenue du 6 juin, 14000 Caen, France. · Université catholique de Louvain, avenue Hippocrate, 10 B-1200 Bruxelles, Belgique. ·Bull Cancer · Pubmed #27456259.

ABSTRACT: -- No abstract --

6 Review [Innovative therapies for metastatic melanoma in elderly patients]. 2015

Du-Thanh, A / Lesage, C / Ferreira, E / Dereure, O / Guillot, B. ·Département de dermatologie, hôpital Saint-Eloi, CHU de Montpellier, université de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France. Electronic address: a-du_thanh@chu-montpellier.fr. · Département de dermatologie, hôpital Saint-Eloi, CHU de Montpellier, université de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France. · Unité d'oncogériatrie, centre Antonin-Balmes, 39, avenue Charles-Flahaut, 34295 Montpellier, France. ·Ann Dermatol Venereol · Pubmed #25986740.

ABSTRACT: The mortality rate for malignant melanoma is higher in elderly patients aged 75 years or more, with over 25% of melanomas being diagnosed in this population. This poorer prognosis might perhaps be improved by emerging targeted therapies and immunotherapy, although these agents must be prescribed with care in this rather fragile population. The purpose of our review of the literature concerning phase-2 and -3 published trials of these innovative molecules was to examine their optimal use in elderly patients presenting metastatic malignant melanoma. Most of the trials examined included elderly patients and some were analyzed by age sub-groups. In conclusion, elderly patients with ECOG 0/1 status can be given ipilimumab or vemurafenib as first-line therapy depending on tumoral BRaf mutation status. The benefit of combined targeted therapies does not seem to apply consistently in elderly patients and their use must be discussed. Further specific data must be collected in elderly patients concerning anti-PD1 molecules. For more fragile patients, risk scales or scores should enable more accurate use of innovative therapies in metastatic melanoma. Moreover, physicians must be aware of the common drug interactions with targeted therapies, since elderly patients are often taking several concomitant drugs.

7 Review [Systemic treatment of melanoma brain metastases]. 2015

Le Rhun, É / Mateus, C / Mortier, L / Dhermain, F / Guillot, B / Grob, J-J / Lebbe, C / Thomas, M / Jouary, T / Leccia, M-T / Robert, C. ·Neuro-oncologie, département de neurochirurgie, hôpital Roger-Salengro, CHRU, rue Émile-Laine, 59037 Lille cedex, France; Oncologie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France; Inserm U1192, laboratoire Prism, université Lille 1, bâtiment SN3 1(er) étage, 59655 Villeneuve-d'Ascq cedex, France; Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France. Electronic address: emilie.lerhun@chru-lille.fr. · Département de dermatologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Département de dermatologie, centre hospitalier régional et universitaire de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France. · Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France; Département de radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Réunion de concertation pluridisciplinaire de neuro-oncologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Département de dermatologie, centre hospitalier universitaire, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France; Université Montpellier 1, 5, boulevard Henri-IV, CS 19044, 34967 Montpellier cedex 2, France. · Département de dermatologie, centre hospitalo-universitaire, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. · Département de dermatologie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de dermatologie, pôle d'oncologie-radiothérapie, de dermatologie et des soins palliatifs, groupe hospitalier Saint-André, centre hospitalier universitaire de Bordeaux, 1, rue Jean-Burguet, 33075 Bordeaux, France. · Clinique de dermatologie, d'allergologie et de photobiologie, centre hospitalier Albert-Michallon, boulevard de la Chantourne, BP 217, 38043 Grenoble cedex 9, France; Inserm U832, institut A.-Bonniot, 38043 Grenoble cedex 09, France. ·Cancer Radiother · Pubmed #25656856.

ABSTRACT: Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) - ipilimumab - or BRAF (serine/threonine-protein kinase B-raf) inhibitors - vemurafenib, dabrafenib - has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).

8 Review [Malignant epithelial and melanocytic skin tumors]. 2012

Guillot, Bernard / Du-Thanh, Aurélie. ·Département de dermatologie, CHU de Montpellier, hôpital Saint-Eloi, 34295 Montpellier Cedex 5, France. b-guillot@chu-montpellier.fr ·Rev Prat · Pubmed #22408878.

ABSTRACT: -- No abstract --

9 Review Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma. 2011

Solassol, Jérôme / Du-Thanh, Aurélie / Maudelonde, Thierry / Guillot, Bernard. ·Laboratoire de Biologie Cellulaire et Hormonale, Hôpital Arnaud de Villeneuve, CHU Montpellier, France. jerome.solassol@univ-montp1.fr ·Int J Biol Markers · Pubmed #21607923.

ABSTRACT: Cutaneous malignant melanoma (CMM) is the most serious type of skin cancer because of its tendency to metastasize. The prognosis and therapeutic management of patients are primarily based on clinical criteria (number of cancerous lymph nodes and/or the presence of distant metastases) and histopathological criteria (tumor depth, presence of ulceration and mitotic index). Although these factors are informative in advanced stages of the disease, they are less important in the early stages. In recent years, a number of attempts have been made to identify new serological prognostic biomarkers, especially for early forms of CMM. The recent development of proteomic techniques may offer new perspectives in this field. This article details the considerations of each of the proteomic techniques used today and describes the results of the most recent clinical studies conducted to identify new potential prognostic serum biomarkers for CMM. However, independent and large validation studies are needed before such markers can be used in everyday clinical practice.

10 Review [Circulating prognosis markers in melanoma: proteomic profiling and clinical studies]. 2011

Solassol, Jérôme / Guillot, Bernard / Maudelonde, Thierry. ·CHU de Montpellier, Hôpital Arnaud-de-Villeneuve, Laboratoire de biologie cellulaire et hormonale, Montpellier. jerome.solassol@univ-montp1.fr ·Ann Biol Clin (Paris) · Pubmed #21464007.

ABSTRACT: Cutaneous melanoma is the most dangerous skin cancer because of its ability to metastasize. Several clinical factors (number of invaded lymph nodes and/or presence of distant metastases) and histopathology (depth of tumor and presence of ulceration) are available to the clinician for determining prognosis and suggesting appropriate therapeutic management. However, these factors are often insufficient, especially in early forms of melanoma. Much research has focused on the identification of effective prognostic markers in serum. The only serum marker, which has been incorporated into the current AJCC classification for clinical use is lactate dehydrogenase dosage, a historical marker, restricted to the prognosis of metastatic disease. The recent development of technologies for proteome analysis offers new perspectives in this field. This review summarizes the specific considerations for each of the proteomic techniques used to date and presents the results of recent clinical investigations conducted to identify prognostic biomarkers in the serum of melanoma patients.

11 Clinical Trial MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. 2018

Dreno, Brigitte / Thompson, John F / Smithers, Bernard Mark / Santinami, Mario / Jouary, Thomas / Gutzmer, Ralf / Levchenko, Evgeny / Rutkowski, Piotr / Grob, Jean-Jacques / Korovin, Sergii / Drucis, Kamil / Grange, Florent / Machet, Laurent / Hersey, Peter / Krajsova, Ivana / Testori, Alessandro / Conry, Robert / Guillot, Bernard / Kruit, Wim H J / Demidov, Lev / Thompson, John A / Bondarenko, Igor / Jaroszek, Jaroslaw / Puig, Susana / Cinat, Gabriela / Hauschild, Axel / Goeman, Jelle J / van Houwelingen, Hans C / Ulloa-Montoya, Fernando / Callegaro, Andrea / Dizier, Benjamin / Spiessens, Bart / Debois, Muriel / Brichard, Vincent G / Louahed, Jamila / Therasse, Patrick / Debruyne, Channa / Kirkwood, John M. ·Department of Dermatooncology, Hotel Dieu Nantes University Hospital, Nantes, France. · Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. · Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia. · Melanoma Sarcoma Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. · Service d'Oncologie Médicale, Hôpital François Mitterrand, Pau, France. · Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany. · Petrov Research Institute of Oncology, St Petersburg, Russia. · Department of Soft Tissue, Bone Sarcoma, and Melanoma, Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland. · Department of Dermatology and Skin Cancers, La Timone APHM Hospital, Aix-Marseille University, Marseille, France. · Department of Skin and Soft Tissue Tumours, National Cancer Institute, Kiev, Ukraine. · Swissmed Centrum Zdrowia, Gdansk, Poland; Department of Surgical Oncology, Gdansk Medical University, Gdansk, Poland. · Dermatology Department, Hôpital Robert Debré, Université de Reims Champagne-Ardenne, Reims, France. · Department of Dermatology, Centre Hospitalier Universitaire, Tours, France; UFR de Médecine, Université François-Rabelais, Tours, France. · Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia. · Dermato-oncology Department, General University Hospital, Prague, Czech Republic. · Columbus Clinic Center, Milan, Italy. · Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. · Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital Saint-Éloi, Montpellier, France. · Department of Medical Oncology, Erasmus MC Cancer institute, Rotterdam, Netherlands. · Cancer Research Center, Moscow, Russia. · Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA. · Department of Oncology and Medical Radiology, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine. · Centrum Medyczne Bieńkowski, Klinika Chirurgii Plastycznej, Bydgoszcz, Poland; Department of Oncological Surgery, Oncology Center, Bydgoszcz, Poland. · Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. · Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina. · Department of Dermatology, Venereology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany. · Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands. · GlaxoSmithKline, Rixensart, Belgium. Electronic address: fernando.x.ulloa-montoya@GSK.com. · GlaxoSmithKline, Rixensart, Belgium. · GlaxoSmithKline, Rixensart, Belgium; Immunology Translational Medicine, UCB, Brussels, Belgium. · GlaxoSmithKline, Rixensart, Belgium; Biostatistics Department, Janssen Research & Development, Beerse, Belgium. · GlaxoSmithKline, Rixensart, Belgium; ViaNova Biosciences, Brussels, Belgium. · GlaxoSmithKline, Rixensart, Belgium; Laboratoires Servier, Paris, France. · GlaxoSmithKline, Rixensart, Belgium; University Hospitals Leuven, Leuven, Belgium. · UPMC Hillman Cancer Center, Pittsburgh, PA, USA. ·Lancet Oncol · Pubmed #29908991.

ABSTRACT: BACKGROUND: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the adjuvant setting. METHODS: DERMA was a phase 3, double-blind, randomised, placebo-controlled trial done in 31 countries and 263 centres. Eligible patients were 18 years or older and had histologically proven, completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma with macroscopic lymph node involvement and an Eastern Cooperative Oncology Group performance score of 0 or 1. Randomisation and treatment allocation at the investigator sites were done centrally via the internet. We randomly assigned patients (2:1) to receive up to 13 intramuscular injections of recombinant MAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic; 300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B to a total volume of 0·5 mL), or placebo, over a 27-month period: five doses at 3-weekly intervals, followed by eight doses at 12-weekly intervals. The co-primary outcomes were disease-free survival in the overall population and in patients with a potentially predictive gene signature (GS-positive) identified previously and validated here via an adaptive signature design. The final analyses included all patients who had received at least one dose of study treatment; analyses for efficacy were in the as-randomised population and for safety were in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT00796445. FINDINGS: Between Dec 1, 2008, and Sept 19, 2011, 3914 patients were screened, 1391 randomly assigned, and 1345 started treatment (n=895 for MAGE-A3 and n=450 for placebo). At final analysis (data cutoff May 23, 2013), median follow-up was 28·0 months [IQR 23·3-35·5] in the MAGE-A3 group and 28·1 months [23·7-36·9] in the placebo group. Median disease-free survival was 11·0 months (95% CI 10·0-11·9) in the MAGE-A3 group and 11·2 months (8·6-14·1) in the placebo group (hazard ratio [HR] 1·01, 0·88-1·17, p=0·86). In the GS-positive population, median disease-free survival was 9·9 months (95% CI 5·7-17·6) in the MAGE-A3 group and 11·6 months (5·6-22·3) in the placebo group (HR 1·11, 0·83-1·49, p=0·48). Within the first 31 days of treatment, adverse events of grade 3 or worse were reported by 126 (14%) of 894 patients in the MAGE-A3 group and 56 (12%) of 450 patients in the placebo group, treatment-related adverse events of grade 3 or worse by 36 (4%) patients given MAGE-A3 vs six (1%) patients given placebo, and at least one serious adverse event by 14% of patients in both groups (129 patients given MAGE-A3 and 64 patients given placebo). The most common adverse events of grade 3 or worse were neoplasms (33 [4%] patients in the MAGE-A3 group vs 17 [4%] patients in the placebo group), general disorders and administration site conditions (25 [3%] for MAGE-A3 vs four [<1%] for placebo) and infections and infestations (17 [2%] for MAGE-A3 vs seven [2%] for placebo). No deaths were related to treatment. INTERPRETATION: An antigen-specific immunotherapeutic alone was not efficacious in this clinical setting. Based on these findings, development of the MAGE-A3 immunotherapeutic for use in melanoma has been stopped. FUNDING: GlaxoSmithKline Biologicals SA.

12 Clinical Trial STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. 2018

Delyon, Julie / Chevret, Sylvie / Jouary, Thomas / Dalac, Sophie / Dalle, Stephane / Guillot, Bernard / Arnault, Jean-Philippe / Avril, Marie-Françoise / Bedane, Christophe / Bens, Guido / Pham-Ledard, Anne / Mansard, Sandrine / Grange, Florent / Machet, Laurent / Meyer, Nicolas / Legoupil, Delphine / Saiag, Philippe / Idir, Zakia / Renault, Victor / Deleuze, Jean-François / Hindie, Elif / Battistella, Maxime / Dumaz, Nicolas / Mourah, Samia / Lebbe, Celeste / Anonymous2300917. ·Service de Dermatologie, and CIC (Centre d'Investigations Cliniques), AP-HP, Hôpital Saint-Louis, Paris, France; INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. Electronic address: julie.delyon@aphp.fr. · Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Biostatistique et Information Médicale, AP-HP, Hôpital Saint-Louis, Paris, France. · Unité Onco-dermatologie, Hôpital François Mitterrand, Pau, France. · Service de Dermatologie, CHU Dijon Bourgogne, Dijon, France. · Cancer Research Center of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France. · Montpellier University Hospital, Montpellier, France. · Service de Dermatologie, CHU Amiens-Picardie, Amiens, France. · Service de Dermatologie, AP-HP, Hôpital Cochin, Paris, France; Université Paris Descartes, Paris, France. · Unité d'oncologie thoracique et cutanée, Hopital Dupuytren, Limoges, France. · Service de Dermatologie, Centre hospitalier régional d'Orléans, Orléans, France. · Dermatology Department, CHU de Bordeaux, Bordeaux, France. · Dermatology Department, CHU de Clermont Ferrand, Clermont Ferrand, France. · Dermatology Department, Reims University Hospital, Reims, France. · Department of Dermatology, Centre Hospitalier Regional et Universitaire (CHRU) de Tours, Tours, France; Inserm U930, University Francois Rabelais de Tours, Tours, France. · Dermatologie, Institut Universitaire du Cancer et CHU de Toulouse, Toulouse, France; Inserm UMR 1037, CRCT, Toulouse, France. · Dermatology Department, University Hospital of Brest, Brest, France. · Université de Versailles St-Quentin, EA 4340, Boulogne-Billancourt, France; Service de Dermatologie Générale et Oncologique, AP-HP, Hôpital Ambroise Paré, Boulogne-Billancourt, France. · AP-HP, Département de la Recherche Clinique et du Développement, AP-HP, Hôpital Saint-Louis, Paris, France. · Laboratory for Bioinformatics, CEPH-Fondation Jean Dausset, Paris, France. · Centre National de Génotypage, CEA, Evry, France; CEPH-Fondation Jean Dausset, Paris, France. · Service de Médecine Nucléaire, CHU de Bordeaux, LabEx TRAIL, Université de Bordeaux, Bordeaux, France. · Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM, UMR_S1165, Paris, France; Pathology department, Hopital Saint-Louis, AP-HP, Paris, France. · INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France. · INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Laboratoire de Pharmacologie Biologique, AP-HP, Hôpital Saint-Louis, Paris, France. · Service de Dermatologie, and CIC (Centre d'Investigations Cliniques), AP-HP, Hôpital Saint-Louis, Paris, France; INSERM, UMR-976, AP-HP, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. ·J Invest Dermatol · Pubmed #28843487.

ABSTRACT: Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array, and immunostaining of downstream KIT effectors were performed during treatment. Twenty-five patients were included and received 400 mg oral nilotinib twice daily. At 6 months, nilotinib induced tumor response in four patients. The best overall response rate was 20% and the disease control rate was 56%, limited to patients harboring exon 11 or 13 mutations. Four patients exhibited durable response, including three persisting (3.6 and 2.8 years for two patients with stage IIIC and 2.5 years for one with IVM1b melanoma). A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response. In the KIT-mutated melanoma cell line M230, nilotinib reduced STAT3 signaling and STAT inhibitors were as efficient as KIT inhibitors in reducing cell proliferation. Our study evidences a significant association between STAT3 inhibition and response to nilotinib, and provides a rationale for future research assessing STAT inhibitors in KIT-mutated melanoma.

13 Clinical Trial Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. 2013

Grob, Jean Jacques / Jouary, Thomas / Dréno, Brigitte / Asselineau, Julien / Gutzmer, Ralf / Hauschild, Axel / Leccia, Marie Thérèse / Landthaler, Michael / Garbe, Claus / Sassolas, Bruno / Herbst, Rudolf A / Guillot, Bernard / Chene, Genevieve / Pehamberger, Hubert. ·Aix-Marseille University, CRO2, Service de Dermatologie, Hopital de Timone, 264 Rue St Pierre, 13885 Marseille CEDEX 05, Marseille, France. jean-jacques.grob@ap-hm.fr ·Eur J Cancer · Pubmed #22975216.

ABSTRACT: AIM: Both low-dose interferon (IFN) alfa-2b and pegylated interferon (Peg-IFN) alfa-2b have been shown to be superior to observation in the adjuvant treatment of melanoma without macrometastatic nodes, but have never been directly compared. Peg-IFN facilitates prolongation of treatment, which could provide additional benefit. This multicentre, open-label, randomised, phase 3 trial compared standard low-dose interferon IFN and prolonged treatment with Peg-IFN. PATIENTS AND METHODS: Patients with resected melanoma ≥1.5mm thick and without clinically detectable node metastases were randomised 1:1 to treatment with IFN 3 MU subcutaneously (SC) three times weekly for 18 months or Peg-IFN 100 μg SC once weekly for 36 months. Sentinel lymph node dissection (SLND) was optional. The primary endpoint was disease-free survival (DFS). Secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS) and adverse events (AEs) grade 3-4. RESULTS: Of 898 patients enrolled, 896 (443 Peg-IFN, 453 IFN) were eligible for evaluation (median follow-up 4.7 years). SLND was performed in 68.2% of patients. There were no statistical differences between the two arms for the primary outcome of DFS (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.73-1.15) or the secondary outcomes of DMFS (HR 1.02, 95% CI 0.80-1.32) and OS (HR 1.09, 95% CI 0.82-1.45). Peg-IFN was associated with higher rates of grade 3-4 AEs (47.3% versus 25.2%; p<0.0001) and discontinuations (54.3% versus 30.4%) compared with IFN. CONCLUSION: This trial did not show superiority for adjuvant Peg-IFN over conventional low-dose IFN in melanoma patients without clinically detectable nodes. ClinicalTrials.gov identifier: NCT00221702.

14 Clinical Trial Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. 2010

Maio, Michele / Mackiewicz, Andrzej / Testori, Alessandro / Trefzer, Uwe / Ferraresi, Virginia / Jassem, Jacek / Garbe, Claus / Lesimple, Thierry / Guillot, Bernard / Gascon, Pere / Gilde, Katalin / Camerini, Roberto / Cognetti, Francesco / Anonymous600652. ·Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. mmaio@cro.it ·J Clin Oncol · Pubmed #20194853.

ABSTRACT: PURPOSE: Thymosin alpha 1 (Talpha1) is an immunomodulatory polypeptide that enhances effector T-cell responses. In this large randomized study, we evaluated the efficacy and safety of combining Talpha1 with dacarbazine (DTIC) and interferon alfa (IFN-alpha) in patients with metastatic melanoma. PATIENTS AND METHODS: Four hundred eighty-eight patients were randomly assigned to five treatment groups: DTIC+IFN-alpha+Talpha1 (1.6 mg); DTIC+IFN-alpha+Talpha1 (3.2 mg); DTIC+IFN-alpha+Talpha1 (6.4 mg); DTIC+Talpha1 (3.2 mg); DTIC+IFN-alpha (control group). The primary end point was best overall response at study end (12 months). Secondary end points included duration of response, overall survival (OS), and progression-free survival (PFS). Patients were observed for up to 24 months. RESULTS: Ten and 12 tumor responses were observed in the DTIC+IFN-alpha+Talpha1 (3.2 mg) and DTIC+Talpha1 (3.2 mg) groups, respectively, versus four in the control group, which was sufficient to reject the null hypothesis that P(0) < or = .05 (expected response rate of standard therapy) in these two arms. Duration of response ranged from 1.9 to 23.2 months in patients given Talpha1 and from 4.4 to 8.4 months in the control group. Median OS was 9.4 months in patients given Talpha1 versus 6.6 months in the control group (hazard ratio = 0.80; 9% CI, 0.63 to 1.02; P = .08). An increase in PFS was observed in patients given Talpha1 versus the control group (hazard ratio = 0.80; 95% CI, 0.63 to 1.01; P = .06). Addition of Talpha1 to DTIC and IFN-alpha did not lead to any additional toxicity. CONCLUSION: These results suggest Talpha1 has activity in patients with metastatic melanoma and provide rationale for further clinical evaluation of this agent.

15 Clinical Trial Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. 2010

Wierzbicka-Hainaut, Ewa / Sassolas, Bruno / Mourey, Laurent / Guillot, Bernard / Bedane, Christophe / Guillet, Gerard / Tourani, Jean Marc. ·Departments of Dermatology, CHU de Poitiers, Institut Claudius Rigaud, Toulouse, France. e.wierzbicka@chu-poitiers.fr ·Melanoma Res · Pubmed #20075758.

ABSTRACT: Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma. The purpose of this study was to test the efficacy and safety of combination therapy with TMZ and cisplatin (CDDP) in patients with metastatic melanoma. Chemo-naive patients with metastatic cutaneous melanoma were included in a phase II study of combined therapy with TMZ (200 mg/m/day), days 1-5, and CDDP (75 mg/m/day) on day 1. The treatment was given every 28 days, for up to six cycles. The primary endpoint was the overall response rate and the secondary endpoints were progression-free survival, probability of survival, and tolerance. Thirty patients were enrolled into this study. Median age was 59 years. A total of 126 cycles were administered. Grade 3 and 4 hematological toxicity was observed in 14 patients (46.6%) and clinical toxicity in seven patients (23.3%). No complete response was observed among the 30 included patients. Five patients (16.7%) achieved a partial response. An additional six patients (20%) showed disease stabilization and 17 patients (56.6%) revealed progressive disease. Median survival and median response duration were 8 and 7.2 months, respectively. One- and 2-year survivals were 36.7 and 13.3%. One- and 2-year progression-free survivals were 13.3 and 3.3%. Our results suggest that concurrent adjunction of CDDP to TMZ regimen increases toxicity according to this schedule and does not improve the outcome of stage IV melanoma. The objective response rate is close to response rates observed with single-agent chemotherapy.

16 Article Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. 2020

Khammari, Amir / Nguyen, Jean-Michel / Leccia, Marie-Thérèse / Guillot, Bernard / Saiagh, Soraya / Pandolfino, Marie-Christine / Knol, Anne-Chantal / Quéreux, Gaëlle / Chiffolettau, Anne / Labarrière, Nathalie / Dréno, Brigitte. ·Dermato-cancérology Department, CHU Nantes, CIC 1413, CRCINA, INSERM, University of Nantes, CHU Nantes-Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France. · SEME, PHU11, Saint-Jacques Hospital, CRCINA, INSERM, University of Nantes, Nantes, France. · Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France. · Département of Dermatology, University of Montpellier, CHU de Montpellier, Montpellier, France. · UTCG, CHU Nantes, Nantes, France. · CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France. · Pharmacovigilance Department, CHU Nantes, Nantes, France. · LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. · Dermato-cancérology Department, CHU Nantes, CIC 1413, CRCINA, INSERM, University of Nantes, CHU Nantes-Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France. brigitte.dreno@atlanmed.fr. · UTCG, CHU Nantes, Nantes, France. brigitte.dreno@atlanmed.fr. ·Cancer Immunol Immunother · Pubmed #32306076.

ABSTRACT: BACKGROUND: Adoptive tumor-infiltrating lymphocytes (TIL) therapy and interleukin-2 (IL-2) have been investigated in melanoma. AIM: To confirm previously observed preventive effects of TIL + IL2 in a subgroup of patients with relapsing metastatic stage III melanoma. METHODOLOGY: Open-label, randomized two-group, multicenter five-year trial in adult stage III melanoma patients with only one invaded lymph node after complete resection. Patients received TIL + IL2 or abstention. TIL + IL2 was administered within 8 weeks after lymph node resection and 4 weeks after. Disease-free survival was assessed every 2 months up to month 18, every 3 months up to month 36 and every 4 months up to 5 years. A once-a-year follow-up was scheduled beyond the five-year follow-up. Safety was assessed throughout the trial. RESULTS: Overall, 49 patients accounted for the modified intent-to-treat and 47 for the PP. Slightly more male than female patients participated; mean age was 57.7 ± 11.4 years in the TIL + IL2 group and 53.5 ± 13.0 years in the abstention group. After 5 years of follow-up, 11/26 patients in the TIL + IL2 group and 13/23 in the abstention group had relapsed. There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p = 0.258), nine patients in the TIL + IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27 - 1.59], p = 0.34). Safety was good. CONCLUSION: We did not confirm results of a previous trial. However, ulceration of the primary melanoma may be considered predictive of the efficacy of TIL in melanoma in adjuvant setting, in a manner similar to interferon α.

17 Article Quality-of-life assessment in French patients with metastatic melanoma in real life. 2020

Kandel, Marguerite / Dalle, Stéphane / Bardet, Aurélie / Allayous, Clara / Mortier, Laurent / Dutriaux, Caroline / Guillot, Bernard / Leccia, Marie-Thérèse / Dalac, Sophie / Legoupil, Delphine / Saiag, Philippe / Montaudie, Henri / Arnault, Jean-Philippe / Brunet-Possenti, Florence / Grob, Jean-Jacques / DeQuatrebarbes, Julie / Beylot-Barry, Marie / Lesimple, Thierry / Aubin, François / Maubec, Eve / Granel-Brocard, Florence / Stoebner, Pierre-Emmanuel / Dupuy, Alain / Dreno, Brigitte / Michiels, Stefan / Lebbe, Céleste / Borget, Isabelle. ·Biostatistics and Epidemiology Service, Gustave Roussy Institute, Villejuif, France. · Center for Research in Epidemiology and Population Health, University of Paris-Saclay, University of Paris-Sud, and Versailles-Saint-Quentin-en-Yvelines University, French Institute of Health and Medical Research (INSERM), Villejuif, France. · Dermatology Unit, Cancer Research Center of Lyon, Lyon University Hospital, Claude Bernard University, Lyon, France. · Dermatology Unit, Clinical Investigation Center, Public Hospital of Paris (AP-HP), INSERM Unit 976, Paris Diderot University-Saint-Louis Hospital, Paris, France. · ONCO-THAI, INSERM Unit 1189, Lille University, Lille Hospital, Lille, France. · Dermatology Unit, Bordeaux Saint-Andre Hospital, Bordeaux, France. · Dermatology Unit, Montpellier Hospital, Montpellier, France. · Dermatology Unit, Grenoble Hospital, Grenoble, France. · Dermatology Unit, Dijon Hospital, Dijon, France. · Dermatology Unit, Brest Hospital, Brest, France. · Dermatology Unit, Ambroise Pare Hospital, AP-HP, Boulogne-Billancourt, France. · Dermatology Unit, Nice Hospital, Nice, France. · Dermatology Unit, Amiens Hospital, Amiens, France. · Dermatology Unit, Bichat Hospital, AP-HP, Paris, France. · Dermatology Unit, La Timone Hospital, Marseilles, France. · Dermatology Unit, Annecy Hospital, Annecy, France. · Dermatology Unit, Bordeaux Haut-L'eveque Hospital, Bordeaux, France. · Rennes Eugene Marquis, Cancer Center, Rennes, France. · Dermatology Unit, Besancon Hospital, Besancon, France. · Dermatology Unit, Avicennes Hospital, AP-HP, Paris, France. · Dermatology Unit, Nancy Hospital, Nancy, France. · Dermatology Unit, Nimes Hospital, Nimes, France. · Dermatology Unit, Rennes Hospital, Rennes, France. · Dermatology Unit, Nantes Hospital, Nantes, France. · Research Group in Law and Health Economics, University Paris-Sud, Paris, France. ·Cancer · Pubmed #31639198.

ABSTRACT: BACKGROUND: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. METHODS: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. RESULTS: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of -0.027 (95% CI, -0.03, -0.02) in the utility score, -1.82 (95% CI, -1.88, -1.76) in the FACT-General score, and -2.98 (95% CI, -3.05, -2.91) in the FACT-Melanoma score compared with first-line treatment. CONCLUSIONS: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.

18 Article HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. 2019

Malissen, Nausicaa / Macagno, Nicolas / Granjeaud, Samuel / Granier, Clémence / Moutardier, Vincent / Gaudy-Marqueste, Caroline / Habel, Nadia / Mandavit, Marion / Guillot, Bernard / Pasero, Christine / Tartour, Eric / Ballotti, Robert / Grob, Jean-Jacques / Olive, Daniel. ·Tumor Immunology Team, IBISA Immunomonitoring platform, Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix-Marseille University, Institut Paoli-Calmettes, Marseille, France. · INSERM, CRCM, APHM, CHU Timone, Department of Dermatology and Skin Cancer, Aix Marseille University, Marseille, France. · INSERM, MMG, APHM, CHU Timone, Department of Pathology, Aix Marseille University, Marseille, France. · UMR_S970, HEGP, Centre de recherche cardio-vasculaire, Paris, France. · APHM, CHU Nord, Department of Digestive surgery, Aix Marseille University, Marseille, France. · INSERM U 1065, Team 1 Nice, Centre Méditerranéen de Médecine Moléculaire, Nice, France. · Department of Dermatology, CHU Montpellier, Montpellier, France. ·Oncoimmunology · Pubmed #31741766.

ABSTRACT: HVEM (Herpes Virus Entry Mediator) engagement of BTLA (B and T Lymphocyte Attenuator) triggers inhibitory signals in T cells and could play a role in evading antitumor immunity. Here, HVEM expression levels in melanoma metastases were analyzed by immunohistochemistry, correlated with overall survival (OS) in 116 patients, and validated by TCGA transcriptomic data. Coincident expression of HVEM and its ligand BTLA was studied in tumor cells and tumor-infiltrating lymphocytes (TILs) by flow cytometry (n = 21) and immunofluorescence (n = 5). Candidate genes controlling

19 Article [Reprint of: New guidelines for stage III melanoma (the French Cutaneous Oncology Group)]. 2019

Guillot, B / Dupuy, A / Pracht, M / Jeudy, G / Hindie, E / Desmedt, E / Jouary, T / Leccia, M-T. ·Département de dermatologie, université de Montpellier, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · Service de dermatologie, CHU de Rennes, 35033 Rennes, France. · Département d'oncologie médicale, centre Eugène-Marquis, 35000 Rennes, France. · Service de dermatologie, CHU de Dijon, Dijon, 21079 France. · Service de médecine nucléaire, CHU de Bordeaux, Bordeaux, 33076 France. · Service de dermatologie, CHU de Lille, 59037 Lille, France. · Service d'oncologie, centre hospitalier de Pau, 64000 Pau, France. · Service de dermatologie, CHU de Grenoble, 38043 Grenoble, France. ·Bull Cancer · Pubmed #31122657.

ABSTRACT: Improved knowledge of sentinel node procedures coupled with the results of adjuvant clinical trials in stage III melanoma have prompted the French Cutaneous Oncology Group to propose new guidelines for the management of stage III melanoma. These guidelines comply with the principles of the evidence-based medicine.

20 Article [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. 2019

Becquart, O / Guillot, B / Bourrain, J-L / Duflos, C / Du-Thanh, A. ·Département de dermatologie, Hôpital Saint-Eloi, 34295 Montpellier cedex 5, France. · Département de dermatologie, Hôpital Saint-Eloi, 34295 Montpellier cedex 5, France. Electronic address: b-guillot@chu-montpellier.fr. · Département d'information médicale, CHU de Montpellier, université de Montpellier, 34295 Montpellier, France. ·Rev Med Interne · Pubmed #31101331.

ABSTRACT: The risk of skin cancer induced by photosensiting drugs is well known. An association between hydrochlorothiazide use and skin cancer has been recently published in some epidemiological studies. A systematic review of case-control or prospectives cohorts showed an increased risk of cutaneous squamous cell carcinoma even if some confusing factors such as tobacco smoking was not analysed. Results are more conflicting for basal cell carcinoma or melanoma. These results do not modify the benefit/risk ratio but should lead to propose preventive mesures: identification of high risk population, avoidance of this drug if possible in immunocompromised patients or with previous skin cancer, regular skin examination in case of long term use of hydrochlorothiazide.

21 Article Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. 2019

Vallet, Anaïs / Oriano, Bastien / Mortier, Laurent / Dalle, Stéphane / Dutriaux, Caroline / Guillot, Bernard / Leccia, Marie-Thérèse / Dalac, Sophie / Saiag, Philippe / Lacour, Jean-Philippe / Legoupil, Delphine / De Quatrebarbes, Julie / Brunet-Possenti, Florence / Lesimple, Thierry / Arnault, Jean-Philippe / Aubin, François / Granel-Brocard, Florence / Stoebner, Pierre-Emmanuel / Maubec, Eve / Dreno, Brigitte / Allayous, Clara / Porcher, Raphaël / Lebbé, Céleste / Anonymous1741185. ·Department of Dermatology, Hôpital St Louis, Paris, France. · Department of Biostatistics, Hôpital Hôtel Dieu, Paris, France. · Department of Dermatology, CHRU Lille, Lille, France. · Department of Dermatology, Hôpital des Hospices Civils de Lyon, Lyon, France. · Department of Dermatology, CHU de Bordeaux St-André, Bordeaux, France. · Department of Dermatology, CHU Montpellier, Montpellier, France. · Department of Dermatology, CHU Grenoble, Grenoble, France. · Department of Dermatology, CHU Dijon, Dijon, France. · Department of Dermatology, CHU Ambroise Paré, Boulogne-Billancourt, France. · Department of Dermatology, CHU Nice, Nice, France. · Department of Dermatology, CHU Brest, Brest, France. · Department of Dermatology, CH Annecy Genevois, Epagny Metz-Tessy, France. · Department of Dermatology, Hôpital Bichat, Paris, France. · Department of Dermatology, CLCC Rennes Eugène Marquis, Rennes, France. · Department of Dermatology, CHU Amiens-Picardie, Amiens, France. · Department of Dermatology, CHRU Besançon, Besançon, France. · Department of Dermatology, CHRU Nancy, Vandoeuvre-Les-Nancy, France. · Department of Dermatology, CHU Nîmes, Nîmes, France. · Department of Dermatology, Hôpital Avicenne, Bobigny, France. · Department of Dermatology, CHU de Nantes, Nantes, France. ·JAMA Dermatol · Pubmed #31042256.

ABSTRACT: Importance: The prognosis of advanced melanoma has been greatly improved by new therapeutic agents and clinicians rely on dynamic signals to drive their therapeutic choices. Although the kinetics of metastatic disease seem to be correlated with survival, progression of the localized disease is not predictable. Objective: To assess whether progression of metastatic disease is associated with the time to the first distant recurrence of melanoma. Design, Setting, and Participants: This study was conducted from March 1, 2013, to September 1, 2017, among 638 adults with unresectable stage III or IV melanoma within the French multicentric prospective cohort MelBase. Patients treated with first-line immunotherapies, targeted therapies, or chemotherapy were included. Patients with unknown primary or de novo metastatic melanoma were not included. Data were analyzed from March 1, 2013, to December 1, 2017. Main Outcomes and Measures: The date of primary excision and time to first distant recurrence, progression-free survival, and overall survival were collected. Cox proportional hazards regression models were planned to assess the association between time to first distant recurrence and progression-free survival or overall survival, which was evaluated in terms of hazard ratio (HR). Time to recurrence was analyzed both as a continuous and categorical variable (<12 months, 12-24 months, and >24 months). Results: A total of 638 patients (272 women and 366 men; median age, 64 years [interquartile range, 52-73 years]) were included in the study. The median time from primary excision to first distant recurrence was 25 months (interquartile range, 12-55 months). There was no evidence of association of the time to recurrence with progression-free survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.99-1.01) or after categorization (12-24 months: HR, 0.75; 95% CI, 0.56-1.02; >24 months: HR, 0.62; 95% CI; 0.47-1.01). There was no evidence of association of the time to recurrence with overall survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.98-1.02) or after categorization (12-24 months: HR, 0.76; 95% CI, 0.54-1.07; >24 months: HR, 0.61; 95% CI, 0.54-1.03). Those results remained nonsignificant after stratification by treatment. Conclusions and Relevance: In the MelBase cohort, time to recurrence of metastatic melanoma appears not to be associated with progression-free survival or overall survival.

22 Article Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. 2019

Tétu, Pauline / Allayous, Clara / Oriano, Bastien / Dalle, Stéphane / Mortier, Laurent / Leccia, Marie-Thérèse / Guillot, Bernard / Dalac, Sophie / Dutriaux, Caroline / Lacour, Jean-Philippe / Saiag, Philippe / Brunet-Possenti, Florence / De Quatrebarbes, Julie / Stoebner, Pierre-Emmanuel / Legoupil, Delphine / Beylot-Barry, Marie / Lesimple, Thierry / Aubin, François / Dreno, Brigitte / Mohamed, Sameh / Ballon, Alice / Porcher, Raphaël / Lebbe, Céleste. ·APHP Dermatology, Department of Dermatology, Paris 7 Diderot University, INSERM U976, Hôpital Saint-Louis, Paris, France. Electronic address: pauline.tetu@hotmail.fr. · APHP Dermatology, Department of Dermatology, Paris 7 Diderot University, INSERM U976, Hôpital Saint-Louis, Paris, France. · Clinical Epidemiology Center, AP-HP, Hôtel-Dieu, Paris, France. · Hospices Civils De Lyon, Pierre-Bénite, France. · Dermatology Department, CHRU Lille, Lille, France. · Dermatology Department, CHU Albert Michalon, Grenoble, University of Grenoble, Grenoble, France. · Dermatology Department, Universitary Hospital of Montpellier, CHU Montpellier, Montpellier, France. · Dermatology, University Hospital of Dijon, Dijon, France. · Dermatology and Pediatric Dermatology Department, Bordeaux Hospital, Bordeaux, France, Bordeaux, France. · Dermatology Department, Nice Hospital, Nice, France, Nice, France. · AP-HP, Dermatology, Ambroise Paré Hospital, Boulogne-Billancourt, France. · AP-HP, Dermatology, Bichat Hospital, Paris, France. · Dermatology, CHR Annecy Genevois, Annecy, France. · Dermatology, CHU de Nimes, Nimes, France. · Dermatology, CHU Brest, Brest, France. · Dermatology, Hôpital Saint-André, CHU de Bordeaux, Université de Bordeaux, Bordeaux, France. · Centre d'Oncodermatologie CLCC/CHU de Rennes, Rennes, France. · Dermatology, CHU de Besançon, Besançon, France. · Dermatology, CHU de Nantes, Nantes, France. · Data Management, AP-HP, Hôpital Saint-Louis, Paris, France. ·Eur J Cancer · Pubmed #30909072.

ABSTRACT: BACKGROUND: Melanoma brain metastases (MBMs) are historically associated with poor prognosis. Radiation therapy is conventionally associated with a high local control rate. Development of targeted therapy and immunotherapy has improved overall survival (OS) and intracranial response rate, but about 50% of patients failed to respond to these novel therapies. The objective of this study was to assess the impact of combined radiotherapy (cRT) on overall survival in a large multicenter real-life prospective cohort of patients with MBM treated with immunotherapy or targeted therapy. PATIENTS AND METHODS: Clinical data from 262 patients with MBM were collected via MelBase, a French multicentric biobank prospectively enrolling unresectable stage III or IV melanoma. Two groups were defined: patients receiving cRT (cRT group) or not receiving cRT (no-cRT group). Primary end-point was OS. Propensity score weighting was used to correct for indication bias. RESULTS: Among the 262 patients, 93 (35%) received cRT (cRT group). The patients were treated with immunotherapy in 69% and 60% and with targeted therapy in 31% and 40% of the cRT and no-cRT groups, respectively. With a median follow-up of 6.9 months, median OS was 16.8 months and 6.9 months in the cRT and no-cRT groups, respectively. After propensity score weighting, cRT was associated with longer OS (hazard ratio = 0.6, 95% confidence interval: 0.4-0.8; p=0.007). Median OS after ponderation was 15.3 months and 6.2 months in the cRT and no-cRT groups, respectively. CONCLUSION: This study shows that cRT may be associated with a significant decrease of 40% in the risk of death in patients with MBM treated with systemic therapy.

23 Article Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. 2018

Kandel, M / Allayous, C / Dalle, S / Mortier, L / Dalac, S / Dutriaux, C / Leccia, M T / Guillot, B / Saiag, P / Lacour, J P / Legoupil, D / Lesimple, T / Aubin, F / Beylot-Barry, M / Brunet-Possenti, F / Arnault, J P / Granel-Brocard, F / Stoebner, P E / Dupuy, A / Maubec, E / Grob, J J / Dreno, B / Rotolo, F / Ballon, A / Michiels, S / Lebbe, C / Borget, I. ·Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France. Electronic address: marguerite.kandel@gustaveroussy.fr. · Dermatology and CIC, Assistance Publique des Hôpitaux de Paris, INSERM U976, University Paris Diderot-Saint-Louis Hospital, Paris, France. · Dermatology, Hospices Civils de Lyon Hospital, Cancer Research Center of Lyon, Claude Bernard University, Lyon France. · Dermatology, Lille Hospital, Lille, France. · Dermatology, Dijon Hospital, Dijon, France. · Dermatology, Bordeaux Saint-André Hospital, Bordeaux, France. · Dermatology, Grenoble Hospital, Grenoble, France. · Dermatology, Montpellier Hospital, Montpellier, France. · Dermatology, Assistance Publique des Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne-Billancourt, France. · Dermatology, Nice Hospital, Nice, France. · Dermatology, Brest Hospital, Brest, France. · CLCC Rennes Eugène Marquis, France. · Dermatology, Besançon Hospital, Besançon, France. · Dermatology, Bordeaux Haut-L'évêque Hospital, Bordeaux, France. · Dermatology, Assistance Publique des Hôpitaux de Paris, Bichat Hospital, Paris, France. · Dermatology, Amiens Hospital, Amiens, France. · Dermatology, Nancy Hospital, Nancy, France. · Dermatology, Nîmes Hospital, Nîmes, France. · Dermatology, Rennes Hospital, Rennes, France. · Dermatology, Assistance Publique des Hôpitaux de Paris, Avicennes Hospital, University Paris 13, France. · Dermatology, La Timone Hospital, Marseille, France. · Dermatology, Nantes Hospital, Nantes, France. · Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France. · Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, France; University Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France; GRADES, University Paris-Sud, France. ·Eur J Cancer · Pubmed #30384014.

ABSTRACT: PURPOSE: Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice. METHODS: Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines. RESULTS: Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months ( CONCLUSION: This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability.

24 Article A family with two cases of melanocytic tumors and fragile X syndrome. 2017

Lesage, Candice / Coupier, Isabelle / Guillot, Bernard. ·aDepartment of Dermatology, Hôpital Saint-Eloi bDepartment of Oncogenetics, Hôpital Arnaud de Villeuneuve, CHU Montpellier, France. ·Melanoma Res · Pubmed #29036014.

ABSTRACT: Fragile X syndrome (FXS), a leading cause of inherited intellectual disability, most commonly results from an expansion of the CGG trinucleotide repeat in the fragile X mental retardation 1 (FMR1) gene to more than 200 copies (full mutation). The FXS phenotype differs by sex and is associated with intellectual and cognitive impairment, characteristic physical features, epilepsy, and/or behavioral challenges including autism spectrum disorder. In this patient population, tumors involving blood cells, digestive organs, the central nervous system, and testes have been described, but melanocytic tumors have not been reported. Here, we describe two maternal cousins with FXS, one of whom has melanoma and the other has atypical nevus syndrome. We discuss possible mechanisms leading to this unusual or possibly coincidental association and the difficulties in the optimal treatment of FXS patients.

25 Article Sporadic Porphyria in a patient with stage II melanoma treated with interferon α. 2017

Reymann, Valerie / Girard, Celine / Dereure, Olivier / Guillot, Bernard / Du Thanh, Aurélie. ·CHU Dermatology Department. France. · CH ST ELOI - DERMATOLOGY MONTPELLIER. France. ·Curr Drug Saf · Pubmed #28464763.

ABSTRACT: Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies. Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.

Next